Lakefront Biotherapeutics NV (LKFT) — Working Capital to Net Assets Ratio
Lakefront Biotherapeutics NV (LKFT) has a Working Capital to Net Assets ratio of 68.6% as of June 2026. Working capital of $2.24 Billion (current assets of $2.31 Billion minus current liabilities of $70.29 Million) is measured against net assets of $3.26 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Lakefront Biotherapeutics NV Working Capital to Net Assets (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of June 2026, the ratio stands at 68.6%, reflecting working capital of $2.24 Billion against net assets of $3.26 Billion USD. Explore LKFT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Working Capital to Net Assets for Lakefront Biotherapeutics NV (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Lakefront Biotherapeutics NV from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Lakefront Biotherapeutics NV's balance sheet.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 90.4% | $2.93 Billion | $3.24 Billion | $3.08 Billion | $152.86 Million | ▼ -13.3 pp |
| 2024 | 103.7% | $3.00 Billion | $2.90 Billion | $3.34 Billion | $335.08 Million | ▼ -19.1 pp |
| 2023 | 122.8% | $3.43 Billion | $2.80 Billion | $3.86 Billion | $428.22 Million | ▼ -24.2 pp |
| 2022 | 147.0% | $3.71 Billion | $2.53 Billion | $4.24 Billion | $522.54 Million | — |